Drugs Made In America Acquisition II Corp. (DMII) stock
DMIINasdaqBlank ChecksFiscal year ends December 31Also trades as DMIIR, DMIIU
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$10.23−0.02 (-0.20%)
Close on Nov 20, 2026Market cap $140.15MP/E –Yield –
Drugs Made In America Acquisition II net income
Net income is the profit left for shareholders after every expense, interest and tax.
Drugs Made In America Acquisition II's net income for the twelve months ending Sep 30, 2026 was $17.68M. For fiscal 2025 it was $4.19M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.19M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.62M | – |
| Q2 FY2026 | Jun 30, 2026 | $4.40M | – |
| Q1 FY2026 | Mar 31, 2026 | $4.34M | – |
| Q4 FY2025 | Dec 31, 2025 | $4.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.16K | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.07K | – |
| Q1 FY2025 | Mar 31, 2025 | -$59.33K | – |
See a number that looks wrong?